CAR-T cell treatments are now routinely used in some blood cancers.

A recent study presented at the American Society of Clinical Oncology, shows that CAR-T cell treatment is a valuable option for those patients who have already tried conventional treatments .

References

1. Daily Mail. Breakthrough in treating one of the deadliest blood cancers: ‘Remarkably effective’ new immunotherapy can slow disease’s progress by 74%

2. ASCO 2023: Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.

3. ASCO 2023: First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.